Blood Biomarkers in Alzheimer's Diagnosis and New Treatment Methods
Prof. Dr. Özlem Güngör Tunçer stated that blood biomarkers such as p-tau217 have provided significant advancements in Alzheimer's diagnosis, and that early diagnosis and new treatments play a critical role.
While significant developments are taking place in the diagnosis and treatment process of Alzheimer's disease, blood tests showing brain pathologies support the diagnosis process. Experts draw attention to the importance of early diagnosis and next-generation treatments.
Alzheimer's Symptoms and Evaluation Process
In Alzheimer's disease, which is the most common cause of dementia, attention must be paid if forgetfulness affects daily life.
Symptoms such as asking the same question at short intervals, forgetting recent events, and difficulty finding words require evaluation.
Blood Tests and Innovations in Diagnosis
In recent years, blood biomarkers have provided significant advancements in Alzheimer's diagnosis and have started to support diagnosis.
Especially tests measuring phosphorylated tau proteins, such as p-tau217, help determine Alzheimer's pathology in the brain.
New Treatment Approaches and Limitations
New treatments targeting the biological process of the disease have begun to be used in suitable patients at an early stage.
Anti-amyloid treatments aim to slow down progression by targeting amyloid proteins in the brain, but they are not suitable for every patient.
Risk Factors and Ways of Prevention
Although there is no method that completely eliminates the risk of dementia, risk factors can be kept under control.
The control of factors such as hypertension, diabetes, smoking, and physical inactivity is of great importance for brain health.